MSD began worldwide recruitment for the trial and subjects are currently being enrolled. In the randomised trial, the ...

The US company’s rabies candidate, RBI-4000, was able to elicit an immune response comparable to Bavarian Nordic’s RavAvert.

The art of saying no in clinical trials goes beyond simply delivering news; it involves maintaining relationships and ...

A new nasal delivery method for amifostine could protect healthy tissue during pancreatic cancer radiation therapy, ...

Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 ...

A new HPV vaccine induced regression of precancerous cervical lesions in 50% of patients and led to viral clearance in some ...

ACLF clinical trials expected to initiate in 1Q253 clinical data readouts expected by year-end 2025 across the ACLF pipeline, including on-going UNVEIL-IT® Phase 2 trialData of on-going Phase 1b ...

The HUMANOID Center at UC San Diego is pioneering organoid research aimed at improving the reliability and reproducibility of ...

Breakthrough research and investor enthusiasm prompted Cullinan Therapeutics to redirect one of its cancer programs toward ...

Q4 2024 Earnings Call Transcript February 6, 2025 Neurocrine Biosciences, Inc. misses on earnings expectations. Reported EPS ...

Glaukos Corporation GKOS is well-poised for growth on the back of favorable clinical trial results and a robust product ...

IDEAYA Biosciences, Inc. (NASDAQ:IDYA – Get Free Report) has earned an average rating of “Moderate Buy” from the sixteen analysts that are covering the firm, Marketbeat.com reports. Two research ...